Sirona Biochem - SRBCF STOCK NEWS

Sirona Biochem Corp. provides updates on recent milestones and strategic decisions, including successful backing of management team at AGM, financing discussions with investment funds, branding of GlycoProteMimTM, preparation for commercialization, and global licensing agreement with Allergan Aesthetics.

Sirona Biochem Corp. partners with Global Beauty Consulting - Cosmetics Laboratory to develop an exclusive premium formulation for GlycoProteMimTM, enhancing its anti-aging benefits. The partnership aims to create a competitive product line under Sirona LaboratoriesTM for a Q1 2025 launch.

Sirona Biochem Corp. announces a non-brokered private placement of up to 10,000,000 units at a price of $0.10 CAD per Unit, with gross proceeds of up to CAD$1,000,000. Each unit consists of one common share and one transferable share purchase warrant, with the company intending to use the proceeds for general working capital purposes. The completion of the Private Placement is subject to customary conditions, including acceptance from the Toronto Stock Exchange Venture. The securities issued will be subject to a hold period in accordance with regulatory requirements.

Sirona Biochem Corp. provided an update on its recent milestones and strategic decisions, including the trademarking of TFC-1326 as GlycoProteMim. The company plans to launch its first product early in the 1st quarter of 2025, not 2024 as previously stated.

Sirona Biochem Corp. announces the trademark of TFC-1326 as GlycoProteMim, a move aimed at enhancing marketability and positioning in the beauty industry. The decision is expected to distinguish the anti-aging active ingredient and make it a sought-after solution for consumers.

Sirona Biochem Corp. introduces Sirona Laboratories, a subsidiary dedicated to maximizing the commercial potential of its anti-aging skincare ingredient, GlycoProteMim. Dr. Howard Verrico, CEO, expressed enthusiasm for the milestone, stating that it will revolutionize the global anti-aging skincare market. The decision to trademark GlycoProteMim follows extraordinary results from clinical trials, prompting the strategic establishment of Sirona Laboratories.

Sirona Biochem Corp. (SBM) has trademarked its anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim™. The company aims to revolutionize the cosmetics industry with this groundbreaking skincare solution, targeting the $12.5 billion global anti-aging market.

Sirona Biochem Corp (OTC: SRBCF) announced strategic corporate changes following an exclusive global licensing agreement with Allergan Aesthetics. The Board is reviewing all company aspects, including management and project pipeline, aiming for sustainable growth. Additionally, organizational enhancements will occur in Vancouver and Rouen, France, to expedite project development. Sirona plans to strengthen its market presence, enhance investor relations, and pursue up listing opportunities. Continuous updates on these initiatives will be provided throughout 2022.

Sirona Biochem has signed a global exclusive licensing agreement with Allergan Aesthetics, a subsidiary of AbbVie, to develop topical skin care treatments using the innovative compound TFC-1067. This collaboration is a validation of the potential of Sirona's platform technology, which has shown success in recent clinical trials. The agreement includes an upfront payment, milestone payments, and royalties on product sales, enhancing Sirona's financial outlook. The partnership with Allergan, known for its expertise in aesthetic medicine, positions Sirona for significant market opportunities.